CDKN2A and neoplasm: Although we did not find CDKN2A homozygous deletion in our studied population, we did find a gene signature of shorter progression-free survival after radiotherapy +/− chemotherapy treatment, showing that independently of CDKN2A homozygous deletion, a subpopulation of patients with ODs have a more aggressive tumor that is less sensitive to treatment including radiotherapy.